Logo Logo
Switch Language to German
Barrio, Martin; Fendler, Wolfgang P.; Czernin, Johannes; Herrmann, Ken (2016): Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. In: Expert Review of Molecular Diagnostics, Vol. 16, No. 11: pp. 1177-1188
Full text not available from 'Open Access LMU'.


Introduction: Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either Ga-68 for positron-emission-tomography (PET) or Lu-177 for radionuclide therapy.Areas covered: In this literature review we evaluate the diagnostic value of Ga-68 PSMA PET/CT and the therapeutic potential of Lu-177 PSMA radioligand therapy (RLT) in patients with prostate cancer. Ga-68 PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management. The preliminary data for Lu-177 PSMA indicates >50% reduction of PSA levels in up to 59% of patients. Severe adverse events occurred <10% of patients after RLT.Expert commentary: PSMA ligands for diagnostic and therapeutic purpose will significantly impact the management of patients with prostate cancer.